Aleva Neurotherapeutics raised €11M in a Series D+ round in Oct 2017. The company is based in Lausanne, Switzerland. Investors in the round: Forrestal Capital. Data as of 7 Aug 2026.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
